Background: We assessed risk factors for viremia and drug resistance among long-term recipients of antiretroviral therapy (ART) in South Africa.
Background
In South Africa, of the approximately 6 million HIV-1infected individuals, more than 600 000 were enrolled into antiretroviral therapy (ART) programs by mid 2009 [1] . The majority of patients receive a first-line regimen that includes two nucleoside reverse-transcriptase inhibitors (NRTIs) and one non-NRTI (NNRTI). The NRTI drug, stavudine, is routinely used, although many patients show intolerability [2] . It is estimated that less than 10% of patients are on a second-line regimen that includes two NRTIs combined with one boosted protease inhibitor (PI) as recommend by the WHO [3, 4] . Although ART delays disease progression and premature death [5, 6] , sustained high adherence to ART is necessary to prolong viral suppression. There are important consequences to viremia on first-line ART including the development of drug resistance mutations and the need to switch to a second-line regimen with considerable cost implications [7, 8] .
Although high levels of adherence to ART have been reported from small-scale HIV programs in sub-Saharan Africa [9, 10] , challenges arise as programs are taken to scale by governments in countries with a growing burden of HIV and tuberculosis (TB), limited healthcare systems and drug supplies [11, 12] . Many studies in southern Africa have examined virologic failure in different populations and shown that a number of factors influence viremia among first-line patients [13, 14] . These include the HIV care setting, payment for ART, the distance traveled from home to clinic and adherence to appointments and medication among others. Some studies have also examined drug resistance among selected patients with virological failure and shown that the majority harbor mutations associated with lamivudine, NNRTIs and thymidine analogue mutations (TAMs) [13, [15] [16] [17] [18] . Here, we aimed to determine the relationship between prevalence of viremia, drug resistance and reported adherence among approximately 1000 longterm recipients of ART, including a proportion on second-line regimens, in Soweto, South Africa.
Methods

Study setting
We conducted a cross-sectional study at two outpatient clinics at the Chris Hani Baragwanath Hospital, the largest hospital in Africa, located in Soweto outside Johannesburg and serving a population of 4 million people [19, 20] . Both clinics are affiliated to the Faculty of Health Sciences at the University of the Witwatersrand in Johannesburg and had access to ART through clinical research trials before the National ART scaleup in 2004. The first clinic is a non-governmental organization (NGO) research clinic [21] with five medical doctors, three nurses, two nursing assistants and two counselors managing an estimated 50 HIV patients per day of the approximately 1500 on ART (i.e. around 300 patients for each medical doctor). The second clinic is a public clinic with eight medical doctors, four nurses, one nursing assistant and seven counselors managing an estimated 200 HIV patient visits per day from approximately 3500 on ART (i.e. around 440 patients for each medical doctor). The study was approved by the research ethics committees at the University of the Witwatersrand and the Regional Medical Ethics Board in Stockholm, Sweden. Written informed consent for conducting an interview and taking a blood sample was obtained from all patients.
Patient recruitment and interview
During March-September 2008, we recruited patients through posters in the clinic and pharmacy waiting areas in the three most widely spoken languages in Soweto: English, Sesotho and isiZulu. Patients interested in the study were provided an information sheet, which included a 50 South African Rands (US$ 5) as a transport reimbursement.
The following inclusion criteria were applied: at least 18 years old; being on ART for at least 12 months; and consenting to participate in the study. We initially enrolled 1000 patients (500 at each site), but reduced the number to 998 individuals after discovering that two patients were interviewed twice at the public clinic.
The interview questionnaire was developed in English, translated into isiZulu and Sesotho then back-translated to English. After piloting, the final questionnaire included 59 questions with a total of 210 items covering socioeconomic background, disclosure, TB treatment, ART side-effects and adherence during the previous weekend [22] which served as a proxy for recent adherence. Two research assistants, trained in nursing and public health and fluent in all three languages, interviewed patients, which took on average 15 min. The questionnaire data were entered into a database using EpiData [23, 24] . A 10-ml blood sample was drawn by the clinic phlebotomist at the time of interview.
Laboratory assessments
CD4 cell counts were done on the day of blood draw using a BD FACSCount (Becton Dickinson BioSciences, Immunocytochemistry Systems, San Jose, California, USA). Plasma viral levels were assessed using the Amplicor HIV-1 Monitor Test, v1.5 (Roche Molecular Diagnostics, Basel, Switzerland) lower limit of detection of 400 HIV RNA copies/ml. For HIV genotyping, viral RNA was isolated from plasma samples with viral load of more than 400 copies/ml using the MagNa Pure LC Total Nucleic Acid Isolation kit (Roche Diagnostics, Indianapolis, Indiana, USA) on the MagNa Pure Automated System (Roche Molecular Diagnostics) and sequenced using an in-house assay at the National Institute for Communicable Diseases (NICD) in Johannesburg [25] . Mutations were identified using the Stanford HIVdb genotypic resistance algorithm and then coded as major resistant mutations using the International AIDS Society (IAS) list from December 2009 [26] . HIV-1 subtype classifications were done using Rega version 2.0 [27] .
Data analysis
We grouped patients by the type of line regimen, that is first-line and second-line, then a number of variables were examined as potential predictors of viremia. For each variable, we first calculated the adjusted odds ratio [adjusted OR, 95% confidence interval (CI)] and P value controlling for sex, education, type of clinic, age and selfreported adherence during the last weekend, which is denoted as the basic adjusted model. The presented adjusted ORs for the five variables in the previous sentence are derived from a regression model including only these covariates.
All variables with P values 0.15 or less in the basic adjusted model were added into a backward selection multiple logistic regression analysis (inclusion criteria was P 0.05). This model is denoted the final model. The adherence variable was included in the model regardless of P value. Stata/SE (version 10.1) was used for data analysis [28] .
Results
Patient characteristics
A total of 998 HIV-1-infected patients receiving ART at either an NGO or public clinic at the same hospital were interviewed for this study (Table 1a ). The majority of the patients were women (75%), who, with a median age of 41 years, were significantly older than the men (median age 37 years) (P < 0.01). Overall, 78% had attained some secondary education, 64% lived in a house, 24% lived in an informal dwelling (shack) and 13% did not own a refrigerator. More than half of the study population was in a partner relationship, 14% were married, approximately 14% cohabitated and 24% reported a sexual relationship but lived alone. Only 3% of all patients reported more than one (>1) sexual partner during the last 3 months and the majority reported using condoms consistently. Seventy percent of patients were unemployed and 7% were working in casual or daily labor. Forty percent of the patients relied on receipt of a disability grant from social services of 940 South African Rands (around US$ 122) per month. Only 38% did not rely on others for monetary support. The vast majority (91%) of patients used public transport to attend outpatient ART clinics.
There were significant differences in the patient populations between the two clinical sites. At the public clinic, there was a higher percentage of men, patients were older, single, lived in informal dwellings, were poor and more likely to be unemployed compared with patients attending the NGO clinic (P < 0.01 for all of the above variables).
Treatment and viremia
More than half (64%) of the study population had been on ART for longer than 36 months (P < 0.01) ( Table 1b ). The majority (89%) were on an NNRTIbased (first-line) and 12% were on a PI-based (secondline). A larger proportion of patients were on secondline therapy at the NGO clinic, which is consistent with this site having a more ART-experienced population. Five percent of patients reported having missed taking their pills during the previous weekend and were classified as incompletely adherent. This was more apparent for the patients attending the NGO clinic (P ¼ 0.03).
Although more than 50% of all patients reported previous treatment for TB, only 2% (n ¼ 18) were receiving TB therapy at the time of study. Among the 14 first-line recipients who were on TB therapy, 13 were on stavudine, lamivudine and efavirenz and one was on zidovudine, lamivudine and efavirenz. We found no significant difference in either median time on ART or median CD4 cell count for TB versus non-TB patients (data not shown).
At enrolment into the study, the median CD4 cell count for the group was 383 cells/ml (range 1-1770). Viremic patients had a significantly lower CD4 cell count (214 cells/ml; range 1-764) compared with those who were suppressed (414 cells/ml; range 40-1770) (P < 0.01). Those at the public clinic had lower CD4 cell counts.
Of the 998 patients, 139 (14%) had a viral load higher than 400 copies/ml and were, therefore, defined as viremic on ART, with a median of 10 500 copies/ml (range 407-1 000 000). There was a higher prevalence of viremic patients at the public clinic compared with the NGO clinic (17 vs. 11%, P ¼ 0.01). Of the viremic patients, 102 were on first-line therapy and 37 were on a second-line regimen with a significant difference in median viral levels (6540 vs. 24 400 copies/ml, respectively, P ¼ 0.01).
Prevalence of HIV drug resistance
Among the 139 patients with viremia, 129 (93%) plasma samples with a median viral load of 13 500 copies/ml were successfully genotyped vs. 10 samples with a median of 2025 copies/ml that could not be amplified (P ¼ 0.04). Of the successfully sequenced samples, 128 were HIV-1 subtype C and one was subtype B. There were no significant differences in the frequency of mutations in samples with viral level below or above 5000 copies/ml (78 vs. 65%, respectively, P ¼ 0.10), which is the recommended cutoff for switching adult patients failing first-line regimens in the South African clinical guidelines at the time of the study [4] .
Risk factors for viremia
In order to determine factors associated with viremia, we performed a multiple logistic regression analysis using a basic adjusted and a final model (see Methods section for description). Among 883 patients on a first-line regimen, viremia was significantly associated with self-reported poor adherence (OR 2.7, 95% CI 1.3-5.6, P ¼ 0.01) during the previous weekend and being on TB treatment in both models (OR 6.4, 95% CI 2.2-18.8, P < 0.01) ( Table 3 ). There was no significant association between viremia and sex, type of clinic and duration of treatment for those on first-line ART. In addition, we found no significant association between viremia and age, education level, being unemployed or income level (data not shown).
For the 115 patients on a second-line regimen, there was a higher risk of virological failure associated with attending the public clinic (OR 4.6, 95% CI 1.8-11.3, P < 0.01) and not having a refrigerator at home (OR 6.7, 95% CI 1.2-37.5, P ¼ 0.03). In the basic adjusted model, receipt of TB treatment was significantly associated with viremia (P < 0.01). As all four TB patients were viremic, it was not possible to fit the final model. There was no risk of viremia associated with reported incomplete adherence during the previous weekend (OR 2.8, 95% CI 0.4-19.6, P ¼ 0.29) unlike what was seen among first-line failures.
Further analysis was done among patients failing first-line therapy with either drug resistance mutant or wild-type viremia. Ninety-six percent of those with drug resistance mutations reported good adherence. In contrast, only 63% of patients exhibiting wild-type virus reported good adherence (P < 0.01, data not shown).
Discussion
In this cross-sectional study among nearly 1000 South African HIV-1-infected patients, the majority of whom had been on ART for more than 3 years, we found a 14% prevalence of viremia, 78% of whom had HIV drug resistance strains. As anticipated, self-reported lapses in adherence to ARTwere strongly associated with viremia. Furthermore, ongoing TB treatment was a risk factor for failing first-line ART. Among second-line ART recipients, virological failure was associated with attending a larger, less-resourced public clinic and not owning a refrigerator. Nevertheless, despite poor socioeconomic conditions, the majority of patients in this study were fully suppressed and highly adherent after many years on ART.
The strongest predictor for viremia was concomitant TB treatment, which may relate to multiple factors such as reduced ART adherence during severe illness, increased pill burden, exacerbation of side-effects and drug interactions with rifampicin, which may reduce NNRTI and PI levels in plasma concentrations [29] . Although studies have not focused specifically on adherence to ART among TB patients, we suspect that adherence to concomitant ART and TB treatment is made difficult for patients when care is not integrated, which increases waiting times and transport costs. In a recent review by Lawn et al. [30] , TB incidence rates on ARTwere shown to decrease over time, but baseline CD4 cell count, sex and socioeconomic conditions still influenced TB acquisition on ART. Given that UNAIDS reports that more than half of TB patients are HIV infected and that in this study most patients had previously received TB treatment, better integration of HIV and TB care should be encouraged [6] .
Not all patients in this study who reported recent poor adherence were viremic at the time of the interview. This may confirm the findings of Rosenblum et al. [31] , who showed that the longer patients are virologically suppressed on ART, the less likely they are to become viremic after missing taking any of their pills. The increased frequency of virologic failure among patients at the public clinic may reflect the higher workload, higher patient-to-provider ratio and more limited resources in the public sector.
Fielding et al. [14] made a similar finding when comparing 39 HIV clinics in South Africa that used the same clinical guidelines. They speculate that this is related to long waiting times at the clinic and/or pharmacy and lack of resources to follow-up patients for their clinic/drug refill appointments. In addition, the patients attending the public clinic were more financially and socially vulnerable than their peers at the NGO clinic; however, they reported higher adherence levels compared with the NGO clinic. We found that patients who did not own a refrigerator were more likely to fail their second-line regimen. Lopinavir/ ritonavir, currently used in South Africa as a prescription of three pills to be taken twice daily, is a soft gel capsule requiring refrigeration, highlighting the need for a heatstable formulation particularly in areas with poor socioeconomic conditions.
Among viremic patients, 78% had resistance mutations and the mutational patterns were similar to recently reported studies from South Africa and other limitedresource countries that use the same first-line regimens [13, 16, 18, [32] [33] [34] [35] [36] [37] . Thus, M184V/I, K103N and V106A/ M were the most common mutations due to lamivudine and NNRTI use. However, in contrast to three other studies from South Africa, there was a relatively lower prevalence of TAMs [15, 16, 18] . Interestingly, among patients failing second-line ART, most were found to harbor drug resistance mutations associated with failure of first-line regimens (particularly the NNRTI mutation, K103N) and there was an extraordinary paucity of PIrelated mutations. This suggests the inability of lopinavir/ ritonavir to select PI resistance mutations at high levels as noted by others [38, 39] and re-emergence of archived mutations from first-line NNRTI regimens.
There are several limitations to this cross-sectional study.
A recent review showed that as many as 50% of patients die or are lost to follow-up during the first 24 months on ART in sub-Saharan Africa [40] . Thus, the patients studied here may represent those who were the most adherent and who remained in treatment, which reduces the sensitivity of identifying risk factors associated with failure. A further caveat is the use of self-reported missed doses over the previous weekend as a proxy for adherence. Although adherence is known to change over time [41] , this measure has been successfully used by others [10, 19, [42] [43] [44] . Given the long-term treatment nature of this cohort and the possibility of recall bias, we chose to use this indicator which was predictive, at least among first-line ART recipients. Patients were recruited through invitation, and we only captured an estimated 10-20% of eligible patients attending either the clinic or the pharmacy, and thus this was not a random sampling. However, the demographic characteristics, including sex, age and marital status, of our study participants are consistent with national statistics and were similar to a larger number studied by Rosen et al. [45] at multiple sites in South Africa. The rate of detection of viremia was consistent with a recent report from South Africa of viremia on ART after 12 months [14] . We were unable to adjust for baseline viral load, CD4 and drug resistance, as these data were not available on all patients. However, the prevalence of transmitted ART resistance among South African patients initiated on ART 2-5 years ago is likely to be low (<5%) [25, 46] .
We found that the majority of viremic patients who were failing their first-line regimen already had regimen-specific drug resistance, irrespective of their viral load level. This confirms the finding by Aleman et al. [47] that drug resistance mutations may occur among viremic patients at low and stable viral load level. These findings underscore the importance of viral load monitoring to identify treatment failure. National guidelines mandate that those with viremia on a first-line regimen be switched to a second-line regimen. Our data showed that approximately a quarter of patients failed without evidence of major drug resistance mutations. These individuals may re-suppress with adherence to first-line drugs [17] , although the presence of minority quasispecies may compromise treatment outcomes [48] , and thus the most appropriate intervention may be to switch to a second-line regimen even in cases of wild-type viremia.
In summary, risk factors for virological failure were line regimen dependent. Increased attention to adherence particularly among those receiving concomitant TB treatment may reduce virologic failure among first-line ART recipients. With the availability of regular subsidised viral load assessments, the public healthcare system in South Africa can identify viremia and initiate second-line treatment. However, further clinical research is needed to identify the causes of second-line failure and improve the response to second-line regimens with alternatives to lopinavir/ritonavir-based treatment. Assessment of drug resistance, in addition to viral load monitoring and adherence counselling before a change in therapy, warrants further investigation.
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